Osteoporosis International - McMaster Experts

publication venue for

EFFECT OF A SINGLE- SHOT INJECTION OF A HIGH-DENSITY HYALURONIC ACID GEL IN PATIENTS WITH SYMPTOMATIC PRIMARY KNEE OSTEOARTHRITIS: RESULTS OF NO-DOLOR STUDY 2021
THE IMPACT OF PHARMACOLOGICAL INTERVENTIONS FOR OLDER ADULTS WITH SARCOPENIA: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS 2021
THE PREVALENCE OF COMMUNITY-DWELLING OLDER ADULTS AT HIGH FRACTURE RISK WHO ARE NOT TAKING OSTEOPOROSIS MEDICATIONS: RESULTS FROM THE CANADIAN LONGITUDINAL STUDY ON AGING (CLSA) 2021
EFFICACY OF LOW DOSE DENOSUMAB IN MAINTAINING BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: A REAL WORLD, PROSPECTIVE OBSERVATIONAL STUDY 2020
RELATIONSHIP BETWEEN OBESITY AND RISK OF MAJOR OSTEOPOROTIC FRACTURE IN POSTMENOPAUSAL WOMEN: TAKING FRAILTY INTO CONSIDERATION 2020
Patient engagement in clinical guidelines development: input from > 1000 members of the Canadian Osteoporosis Patient Network 2020
AN OVERVIEW OF THE ETIOLOGY, CLINICAL MANIFESTATIONS, MANAGEMENT STRATEGIES AND COMPLICATIONS OF HYPOPARATHYROIDISM FROM THE CANADIAN NATIONAL HYPOPARATHYROIDISM REGISTRY 2019
COMBINING FRAILTY AND TRABECULAR BONE SCORE IN PREDICTING RISK OF MAJOR OSTEOPOROTIC FRACTURES 2019
FRAILTY INTERVENTIONS TO IMPROVE PHYSICAL PERFORMANCE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS 2019
IN VIVO ELEMENTAL ANALYSIS OF HUMAN CALCIFIED TISSUE 2019
PATIENT ENGAGEMENT IN CLINICAL GUIDELINES DEVELOPMENT: INPUT FROM > 1000 MEMBERS OF THE CANADIAN OSTEOPOROSIS PATIENT NETWORK 2019
EXERCISE TO IMPROVE FUNCTIONAL OUTCOMES IN PERSONS WITH OSTEOPOROSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2018
FRAILTY AND RISK OF FRAGILITY FRACTURES IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS 2018
FRAILTY AND RISK OF FRAGILITY FRACTURES IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS 2018
MEASURING STRONTIUM IN BONE 2018
A LARGE NUMBER OF FRAIL OLDER ADULTS LIVING IN LONG TERM CARE HOMES ARE AT HIGH RISK FOR HIP FRACTURE 2017
AN OVERVIEW OF THE ETIOLOGY, CLINICAL MANIFESTATIONS, MANAGEMENT STRATEGIES AND COMPLICATIONS OF HYPOPARATHYROIDISM FROM THE CANADIAN NATIONAL HYPOPARATHYROIDISM REGISTRY 2017
CHRONIC INFLAMMATION AND BONE STRUCTURE. THE POTENTIAL PROTECTIVE ROLE OF BIOLOGIC AGENTS IN THE TREATMENT OF CHRONIC ARTHRITIDES 2017
CLINICAL FACTORS PREDICTA GREATER INCREASE IN SPINE BONE DENSITY AFTER LACTATION (FACTORS AFFECTING BONE FORMATION AFTER BREASTFEEDING PILOT STUDY [FABB-PILOT]) 2017
FRACTURE RISK REDUCTION WITH ROMO-SOZUMAB: RESULTS OF A PHASE 3 STUDY IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS 2017
FRAX PREDICTS FRACTURE RISK IN PATIENTS WITH NON-DIALYSIS CHRONIC KIDNEY DISEASE 2017
GLUCOCORTICOID INDUCED OSTEOPOROSIS 2017
INTER-RATER RELIABILITY OF DARTFISH MOVEMENT ANALYSIS SOFTWARE FOR MEASURING MAXIMUM FLEXION AND EXTENSION AT THE HIP AND KNEE IN OLDER ADULTS WITH OSTEOPOROSIS AND OSTEOPENIA 2017
ROMOSOZUMAB RAPIDLY REDUCES CLINICAL VERTEBRAL FRACTURE INCIDENCE: RESULTS FROM THE FRAME STUDY 2017
THE EFFECT OF BONE-SEEKING ELEMENTS PRESENT IN BONE ON DUAL-ENERGY X-RAY ABSORPTIOMETRY AND QUANTITIVE ULTRASOUNDMEASUREMENTS: A PHANTOM STUDY 2017
GASTROINTESTINAL EVENTS AND ASSOCIATION WITH QUALITY OF LIFE AMONG OSTEOPOROSIS PATIENTS: 12 MONTH OBSERVATIONS FROM THE MUSIC OS EUROPE AND CANADA STUDY 2016
GASTROINTESTINAL EVENTS AND ASSOCIATION WITH TREATMENT SATISFACTION AMONG OSTEOPOROTIC PATIENTS: 12 MONTH OBSERVATIONS FROM THE MUSIC OS EUROPE AND CANADA STUDY 2016
SUCCESSFUL MUSCULOSKELETAL AGING 2016
THE DEVELOPMENT OF A ONE YEAR FRACTURE PREDICTION TOOL FOR ABSOLUTE HIP FRACTURE RISK IN THE FRAIL ELDERLY 2016
THICKER AND DENSER CORTICES BUT LESS INTACT TRABECULAE ARE ASSOCIATED WITH ATYPICAL FEMUR FRACTURES: A CROSS-SECTIONAL CASE-COHORT ANALYSIS 2016
OSTEOPOROSIS THERAPY: LONG-TERM BENEFITS AND RISKS 2015
LIFE AFTER PROXIMAL HUMERUS FRACTURE: SETTING PRIORITIES IN HEALTH RESEARCH USING A MODIFIED DELPHI CONSENSUS APPROACH 2015
MONITORING OF OSTEOPOROSIS TREATMENTS 2015
THE ASSOCIATION OF GASTROINTESTINAL EVENTS ON ADHERENCE TO OSTEOPOROSIS TREATMENT AMONG OSTEOPOROTIC WOMEN: RESULTS OF THE MEDICATION USE PATTERNS, TREATMENT SATISFACTION AND INADEQUATE CONTROL OF OSTEOPOROSIS STUDY (MUSIC-OS) 2015
THE RATE OF SELF-REPORTED GASTROINTESTINAL EVENTS AMONG OSTEOPOROTIC WOMEN: RESULTS OF THE MEDICATION USE PATTERNS, TREATMENT SATISFACTION AND INADEQUATE CONTROL OF OSTEOPOROSIS STUDY (MUSIC-OS) 2015
WHAT TRIGGERS OSTEOPOROSIS THERAPY IN HIGH RISK RESIDENTS LIVING IN LONG TERM CARE (LTC) HOMES? THE GAINING OPTIMAL OSTEOPOROSIS ASSESSMENTS IN LONG-TERM CARE (GOAL) STUDY 2015
12-MONTH PERSISTENCE WITH DENOSUMAB THERAPY AMONG OSTEOPOROTIC WOMEN IN THE CANADIAN PATIENT-SUPPORT PROGRAM 2014
ANTIOSTEOPOROSIS MEDICATION USE REMAINS LOW AFTER FRACTURE BUT IS RELATED TO SELF PERCEIVED FRACTURE RISK: FINDINGS FROM THE GLOW STUDY 2014
EFFECT OF TERIPARATIDE ON HEALING OF INCOMPLETE ATYPICAL FEMUR FRACTURES 2014
FRACTURE PATTERNS WITH SELECTIVE SEROTONIN RECEPTOR INHIBITOR, PROTON PUMP INHIBITOR AND GLUCOCORTICOIDS USE IN GLOW 2014
FURTHER REDUCTION IN NONVERTEBRAL FRACTURE RATE IS OBSERVED FOLLOWING 3 YEARS OF DENOSUMAB TREATMENT: RESULTS WITH UP TO 7 YEARS IN THE FREEDOM EXTENSION 2014
HOW WELL DOES SELF-PERCEPTION OF FRACTURE RISK RELATE TO FRACTURE PROBABILITY USING FRAX? FINDINGS FROM THE GLOW STUDY 2014
NOVEL DIAGNOSTIC TOOL: IN VIVO BONE STRONTIUM QUANTIFICATION, RECENT DEVELOPMENTS 2014
OSTEONECROSIS OF THE JAW: REPORT FROM THE INTERNATIONAL ONJ TASK FORCE 2014
OSTEOPOROSIS THERAPY, BEYOND FRACTURE PREVENTION 2014
PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS 2014
RECOMMENDATIONS FOR OSTEOPOROSIS MANAGEMENT AND FRACTURE PREVENTION FOR THE FRAIL ELDERLY IN LONG-TERM CARE (LTC) 2014
RELATIONSHIP OF WEIGHT, HEIGHT, AND BODY MASS INDEX WITH FRACTURE RISK AT DIFFERENT SITES IN POSTMENOPAUSAL WOMEN: THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN (GLOW) 2014
TOO FIT TO FRACTURE: INTERNATIONAL CONSENSUS TO ESTABLISH RECOMMENDATIONS ON EXERCISE AND SAFE MOVEMENT FOR INDIVIDUALS WITH OSTEOPOROSIS AND SPINE FRACTURES 2014
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF ALENDRONATE (ALN) ON BONE MINERAL DENSITY (BMD) AND BONE TURNOVER IN PERIMENOPAUSAL WOMEN WITH LOW BMD 2014
DEVELOPMENT OF RECOMMENDATIONS FOR RADIOLOGISTS REGARDING THE EVALUATION AND MANAGEMENT OF OSTEOPOROSIS WHEN REPORTING MAJOR OSTEOPOROTIC FRACTURES IN THOSE OVER AGE 50 2014
ROLE OF SELF-EFFICACY BASED MODEL OF INTERVENTION: LEARN APPROACH IN REHABILITATION OF DISTAL RADIUS FRACTURE 2014
AN UPDATED CASE STUDY: MONITORING OF BONE STRONTIUM OVER FIVE YEARS OF SELF-SUPPLEMENTATION OF STRONTIUM CITRATE IN AN OSTEOPOROTIC FEMALE 2013
DENOSUMAB (DMAB) TREATMENT FOR 6 YEARS MAINTAINS LOW FRACTURE INCIDENCE IN WOMEN >= 75 YEARS WITH POSTMENOPAUSAL OSTEOPOROSIS (PMO) 2013
DENOSUMAB REDUCED OSTEOPOROTIC FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS WITH PRIOR FRACTURE: RESULTS FROM FREEDOM 2013
EFFECT OF TERIPARATIDE ON FRACTURE HEALING IN PATIENTS WITH NONDISPLACED INCOMPLETE ATYPICAL FEMUR FRACTURES 2013
EFFICACY OF INPATIENT REHABILITATION AFTER OSTEOPOROTIC HIP FRACTURES ON FEMALE ABOVE 75 WITH NEUROLOGICAL IMPAIRMENT 2013
FUNCTIONAL RECOVERY AFTER OSTEOPOROTIC HIP FRACTURES IN FEMALE POPULATION ABOVE 75 REGARDING MUSCULOSKELETAL COMORBIDITY 2013
HOW PRIMARY CARE PHYSICIANS (PCPS) ASSESS POSTMENOPAUSAL WOMEN FOLLOWING EDUCATION ON THE 2010 OSTEOPOROSIS CANADA GUIDELINES 2013
OSTEOPOROSIS AND OSTEOARTHRITIS: SIMILARITIES AND DIFFERENCES 2013
OSTEOPOROSIS AND VERTEBRAL FRACTURES ARE IMPORTANT DETERMINANTS OF CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS 2013
VERTEBRAL FRACTURE ASSESSMENT-DETECTED ABDOMINAL AORTIC CALCIFICATION AND CARDIOVASCULAR DISEASE IN RHEUMATOID ARTHRITIS 2013
HYPERPARATHYROIDISM 2012
BONE AND MUSCLE CHANGES WITH TERIPARATIDE THERAPY FOR 18 MONTHS - A PILOT PROSPECTIVE STUDY FROM A CONVENIENCE COHORT 2012
DENOSUMAB INCREASES TOTAL HIP BONE MINERAL DENSITY IN OLDER WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS 2012
FIVE-YEAR INCIDENT FRACTURE RISK ASSESSED BY QUANTITATIVE MULTISITE ULTRASOUND: THE CANADIAN MULTICENTRE OSTEOPOROSIS STUDY 2012
FRACTURE INCIDENCE IN OBESE POSTMENOPAUSAL WOMEN: THE GLOBAL STUDY OF OSTEOPOROSIS IN WOMEN (GLOW) 2012
LONG-TERM IMPACT OF ADHERENCE TO ORAL BISPHOSPHONATES ON OSTEOPOROTIC FRACTURE INCIDENCE 2012
RECOMMENDATION FOR MEASURING CLINICAL OUTCOME IN DISTAL RADIUS FRACTURES 2012
RELIABILITY OF PQCT-DERIVED MUSCLE AREA AND DENSITY MEASURES ON WATERSHED VS. THRESHOLD-BASED SEGMENTATION METHODS 2012
UNDERSTANDING AND USE OF THE 2010 OSTEOPOROSIS CANADA CLINICAL PRACTICE GUIDELINES (OC CPG) BY CANADIAN PRIMARY CARE PHYSICIANS (PCPs) 2012
EFFECT OF CO-MORBIDITIES ON FRACTURE RISK: FINDINGS FROM THE GLOW STUDY 2011
EFFECT OF ONCE-YEARLY ZOLEDRONIC ACID IN MEN AFTER RECENT HIP FRACTURE: RESULTS FROM HORIZON RECURRENT FRACTURE TRIAL 2011
EXPLORING DIFFERENCES IN BONE DENSITY AND STRUCTURE BETWEEN PATIENTS ON BISPHOSPHONATES WITH ATYPICAL FEMUR FRACTURES AND OTHER POPULATIONS 2011
THE ROLE OF NUTRITION IN THE WAY BONE AND MUSCLE RELATE TO PHYSICAL FUNCTION IN WOMEN 2011
VALIDATION AND CALIBRATION OF 1.0T PERIPHERAL MRI-DERIVED BONE STRUCTURAL MEASURES WITH HIGH-RESOLUTION PERIPHERAL QCT 2011
VALIDATION AND CALIBRATION OF 1.0T PERIPHERAL MRI-DERIVED BONE STRUCTURAL MEASURES WITH HIGH-RESOLUTION PERIPHERAL QCT 2011
DENOSUMAB REDUCED THE INCIDENCE OF HIP AND NEW VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN WITH HIGHER FRACTURE RISK: A SUBANALYSIS OF THE FREEDOM STUDY 2010
MONITORING INCORPORATION OF STRONTIUM CITRATE IN HUMAN BONE 2010
CALCIUM AND VITAMIN D INTAKE IN RESIDENTS LIVING IN LONG-TERM-CARE (LTC) HOMES: THE VITAMIN D OSTEOPOROSIS STUDY (VIDOS) 2010
CLINICAL RISK FACTORS FOR RECURRENT FRACTURE AFTER HIP FRACTURE 2010
DEFINING FRACTURE RISK IN WOMEN USING THE RECOMMENDATIONS FOR BONE MINERAL DENSITY (BMD) REPORTING IN CANADA 2010
HIGH VERSUS LOW DOSE VITAMIN D IN ACUTE HIP FRACTURE PATIENTS: A RANDOMISED, CONTROLLED TRIAL 2010
LOW ENERGY SUBTROCHANTERIC FRACTURES IN PATIENTS RECEIVING BISPHOSPHONATE THERAPY 2010
MECHANICAL LOADING MODULATES THE RELATIONSHIP BETWEEN AREAL BMD AND BONE STRUCTURE 2010
SUBTROCHANTERIC FRACTURES: RESULTS FROM THE HORIZON-RECURRENT FRACTURE TRIAL 2010
SUSTAINED EFFICACY OF BAZEDOXIFENE IN PREVENTING FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS OF A 5-YEAR, RANDOMIZED, PLACEBO-CONTROLLED STUDY 2010
USE OF BISPHOSPHONATE THERAPY IN RESIDENTS LIVING IN LONG-TERM-CARE (LTC) FACILITIES WHO ARE AT HIGH RISK FOR FRACTURES: THE VITAMIN D OSTEOPOROSIS STUDY (VIDOS) 2010
ZOLEDRONIC ACID IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HIP FRACTURE: RESULTS OF HORIZON-RFT 2010
EFFECT OF ONCE-YEARLY IV ZOLEDRONIC ACID IN MEN AFTER HIP FRACTURE: RESULTS FROM THE HORIZON-RECURRENT FRACTURE TRIAL 2009
A NOVEL PERFORMANCE-BASED MEASURE OF FUNCTIONAL RISK FOR OSTEOPOROTIC FRACTURE HAS EXCELLENT RELIABILITY AND GOOD CONVERGENT CONSTRUCT VALIDITY 2009
ASSESSMENT OF FRACTURE RISK AND RECOMMENDATION FOR OSTEOPOROSIS TREATMENT IN WOMEN UNDERGOING THEIR FIRST DEXA SCAN: A COMPARISON BETWEEN BMD, BONE DESTINY AND OSTEOPOROSIS CANADA GUIDELINES 2009
ASSESSMENT OF FRACTURE RISK AND TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: A COMPARISON OF BMD, BONE DESTINY AND OC GUIDELINES 2009
BONE DESTINY: A ONE-STEP GLOBAL FRACTURE RISK PREDICTOR FOR CLINICIANS 2009
DISTRIBUTION OF RISK FACTORS FOR FRACTURE IN WOMEN WITH AND WITHOUT A FRACTURE HISTORY: A REGIONAL COMPARISON. THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN 2009
FAILURE TO PERCEIVE INCREASED RISK OF FRACTURE IN WOMEN 55 YEARS AND OLDER: THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN 2009
FRACTURE RISK ASSESSMENT AND TREATMENT RECOMMENDATIONS IN FEMALES WITH FRAGILITY FRACTURES ASSESSED BY BMD, BONE DESTINY AND OSTEOPOROSIS CANADA GUIDELINES 2009
FRACTURE RISK ASSESSMENT AND TREATMENT RECOMMENDATIONS IN MALES WITH FRAGILITY FRACTURES ASSESSED BY BMD, BONE DESTINY AND OSTEOPOROSIS CANADA GUIDELINES 2009
FRAGILITY FRACTURES AND HEALTH STATUS IN A MULTINATIONAL COHORT: THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN 2009
REGIONAL DIFFERENCES IN THE MANAGEMENT OF OSTEOPOROSIS: THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN 2009
RELIABILITY AND VALIDITY OF A MODIFIED VERSION OF THE SAFE FUNCTIONAL MOTION TEST-SHORT FORM FOR ASSESSING MOVEMENT PATTERNS IN INDIVIDUALS WITH LOW BONE MASS 2009
RISK FACTORS FOR FRAGILITY FRACTURE IN A MULTIRACIAL COHORT OF US WOMEN: THE GLOBAL LONGITUDINAL STUDY OF OSTEOPOROSIS IN WOMEN 2009
VALIDITY OF THE STRENGTH AND FLEXIBILITY DOMAINS COMPRISING A NOVEL PERFORMANCE-BASED MEASURE OF FUNCTIONAL RISK FOR OSTEOPOROTIC FRACTURE 2009
TERIPARATIDE USE IN CANADA: WHICH PATIENTS ARE MOST LIKELY TO PERSIST? 2009
Primary care physicians utilization of drug therapies improves in patients with severe osteoporosis following a multifaceted osteoporosis educational intervention: Canadian quality circle (CQC) pilot project 2007
Medial tibial and femoral cartilage volume and thickness measurements correlate with pain and function in individuals with knee OA 2007
Minimum joint space width values in healthy individuals and patients with knee OA 2007
The contribution of medial femoral and tibial cartilage thickness to minimum joint space width in osteoarthritic knees 2007
Oncostatin M: Anabolic action in bone generation 2006
The use of selective serotonin reuptake inhibitors and fragility fractures: Results from the CaMos study 2006
A comparison of fracture risk classification systems and estimated rates of treatable osteoporosis 2006
Alendronate in primary hyperparathyroidism: Efficacy in men and premenopausal women 2006
Appropriateness of care in osteoporotic and elevated risk patients in Canada: The expertmd in osteoporosis project 2006
Bisphosphonate therapy and the therapeutic care gap in women who have fragility fractures: The Canadian multicentre osteoporosis study (CaMos) 2006
Bisphosphonate use in elderly nursing home residents 2006
Bone erosions detected by peripheral mri at the metacarpophalangeal (MCP) and wrist joints in subjects with and without rheumatoid arthritis 2006
Bone health status in children and youth with cystic fibrosis: Association with body size, physical activity and vitamin D and K status 2006
Compliance, acceptance, and safety of teriparatide injection over 18 months in patients with severe osteoporosis 2006
Costs of fragility fractures among men are considerable in managed care 2006
Dedicated RF coil design for 1T magnetic resonance imaging of trabecular bone at distal radius 2006
Diagnostic and therapeutic care gap in both women and men who have been told they have osteoporosis: The Canadian multicentre osteoporosis study (CaMos). 2006
Do patients with fragility fractures perceive themselves to be at risk of future fracture? 2006
Early life leptin status as a predictor of bone and fat composition in children at pre-puberty 2006
Economic evaluation of aclasta (R) (zoledronic acid 5 mg) versus actonel (R) (risedronate) in treatment of Paget's disease 2006
Expanding the clinical picture of osteoporosis 2006
Family physicians' awareness of key risk factors for fracture and the use of bone mineral density (BMD) testing following a multifaceted osteoporosis educational intervention: Canadian quality circle (CQC) national project 2006
Family physicians' utilization of bone mineral density (BMD) testing in patients with key risk factors following a multifaceted osteoporosis educational intervention: Canadian quality circle (CQC) pilot project 2006
Fragility fracture prevalence in women and men according to T-score values: The Canadian multicentre osteoporosis study (CAMOS) 2006
Low physical activity, body size and caliucm intake as predictors of bone health status in children and youth treated with anti-epileptic drugs 2006
Low rates of vitamin D supplementation in Canadians with low bone mass or fractures 2006
Magnetic resonance imaging scoring system for knee disorders in patients with osteoarthritis or anterior cruciate ligament injury 2006
Measures of distal radial bone geometry predict fracture load 2006
Numerical analysis of Colles' fracture 2006
Osteoporosis information needs and preferences in fragility fracture patients 2006
Quality of life in patients with osteoporosis: Assessment of pain and function 2006
Sub-optimal vitamin D status in children and youth with diseases associated with low bone mass 2006
The bisphosphonate treatment care gap in community dwelling men who have incident fragility fractures: The Canadian multicentre osteoporosis study (CAMOS) 2006
The rate that family physicians prescribe bisphosphonates to their patients: Canadian quality circles (CQC) national project 2006
Articular cartilage volume and thickness measurements correlate with pain and function in individuals with medial tibiofemoral knee OA 2006
Economic evaluation of Aclasta (TM) (zoledronic acid 5 mg) versus Actonel (TM) (risedronate) in treatment of Paget's disease 2006
Medial tibiofemoral minimum joint space width measurements correlate with pain and function in individuals with knee OA 2006
Vertebral fracture risk reduction is independent of the magnitude of BMD change 2004
Magnitude of BMD change is a poor predictor of vertebral fracture risk reduction 2004
Contribution to the screening of bone mineral density through the calcaneo osteosonometry method in women older than 45 years old in the Perola Byington Hospital 2004
Longer term effectiveness outcomes of noncompliance and nonpersistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care 2004
Rapid resolution of the reduction of bone turnover markers after discontinuation of risedronate in postmenopausal women with osteoporosis previously treated for 2 years 2004
Trickery, deception and economic evaluations: Is there more harm than good? 2004
Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: The aware survey 2003
Imaging abnormalities in the knee of asymptomatic individuals identified using peripheral MRI 2003
Probabilistic cost-effectiveness analyses of long term management therapies for postmenopausal osteoporosis: Cautions and concerns of results obtained from traditional deterministic sensitivity analyses 2003
Risk factors that predict new fractures in postmenopausal women: The Canadian database for osteoporosis and osteopenia (CANDOO) 2003
The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women 2003
The effectiveness of etidronate and alendronate in the treatment of osteoporosis in women with a history of breast cancer: The Canadian database for osteoporosis and osteopenia (CANDOO) 2003
The relations between bone mineral density in the spine, hip, distal femur and proximal tibia and medial minimum joint space width in the knees of healthy men and women 2003
Vertebral fracture risk reduction with risedronate in postmenopausal women with osteoporosis: A meta-analysis of individual patient data 2003
CANDOO: A longitudinal canadian multicenter tertiary-care network for observational research in osteoporosis (OP) and osteopenia using standardized clinical practice data: 11 years of follow-up 2002
Colles' fracture and subsequent hip-fracture risk in men: A meta-analysis 2002
Iliocostal distance (ILCD) is associated with prevalent vertebral (VERT) and non-vertebral (NV) fractures in patients registered in the Canadian database of osteoporosis and osteopenia (CANDOO) 2002
Once-a-week (35 mg) risedronate is as effective as daily (5 mg) 2002
The accuracy of height loss during prospective monitoring for detection of incident vertebral fractures 2002
The prevalence of secondary causes of osteoporosis 2002
What is the morbidity of mild vertebral fractures? 2002
A meta analysis of calcium supplementation for the prevention of postmenopausal osteoporosis 2000
Effect of vitamin D in patients with declining vertebral bone mineral density despite stable bisphosphonate therapy 2000
Effectiveness of etidronate and alendronate in the treatment of osteoporosis in males: A prospective observational study 2000
Patient compliance with bisphosphonate therapy 2000
Vertebral fractures and quality of life 2000
Clinical and demographic factors determining patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project.. 1-10. 2024
Race-specific FRAX models are evidence-based and support equitable care: a response to the ASBMR Task Force report on Clinical Algorithms for Fracture Risk. 35:1487-1496. 2024
Correction: Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. 35:933-934. 2024
Geographic variation in bone mineral density and prevalent fractures in the Canadian longitudinal study on aging. 35:599-611. 2024
Hypophosphatasia: presentation and response to asfotase alfa. 35:717-725. 2024
Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. 35:431-438. 2024
Patients’ preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. 35:451-468. 2024
The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance. 35:439-449. 2024
Proposed diagnostic criteria for the diagnosis of hypophosphatasia in children and adolescents: results from the HPP International Working Group. 35:1-10. 2024
International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures. 34:1065-1074. 2023
Post hip fracture orthogeriatric care—a Canadian position paper addressing challenges in care and strategies to meet quality indicators. 34:1011-1035. 2023
Publisher Correction: International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures. 34:1139-1139. 2023
Variation in bone mineral density and fractures over 20 years among Canadians: a comparison of the Canadian Multicenter Osteoporosis Study and the Canadian Longitudinal Study on Aging. 34:357-367. 2023
Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy. 34:147-160. 2023
Race/ethnic differences in the prevalence of osteoporosis, falls and fractures: a cross-sectional analysis of the Canadian Longitudinal Study on Aging. 33:2637-2648. 2022
Fracture definitions in observational osteoporosis drug effects studies that leverage healthcare administrative (claims) data: a scoping review. 33:1837-1844. 2022
Population screening for fracture risk in postmenopausal women — a logical step in reducing the osteoporotic fracture burden?. 33:1631-1637. 2022
Predictive performance of the Garvan Fracture Risk Calculator: a registry-based cohort study. 33:541-548. 2022
The global approach to rehabilitation following an osteoporotic fragility fracture: A review of the rehabilitation working group of the International Osteoporosis Foundation (IOF) committee of scientific advisors. 33:527-540. 2022
Hip fracture predicts subsequent hip fracture: a retrospective observational study to support a call to early hip fracture prevention efforts in post-fracture patients. 33:113-122. 2022
Response to Letter from Prof Aspen, re. "Advanced 2D image processing technique to predict hip fracture risk in an older population based on single DXA scans". 32:2595-2595. 2021
Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis. 32:1713-1723. 2021
Incremental costs of fragility fractures: a population-based matched -cohort study from Ontario, Canada. 32:1753-1761. 2021
Exploring changes in bone mass in individuals with a chronic spinal cord injury. 32:759-767. 2021
A scorecard for osteoporosis in Canada and seven Canadian provinces. 32:123-132. 2021
Advanced 2D image processing technique to predict hip fracture risk in an older population based on single DXA scans. 31:1925-1933. 2020
Teriparatide improves microarchitectural characteristics of peri-implant bone in orchiectomized rats. 31:1807-1815. 2020
Describing the resource utilisation and costs associated withvertebral fractures: the Build Better Bones with Exercise (B3E) Pilot Trial. 31:1115-1123. 2020
Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study. 31:1145-1153. 2020
Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. 31:973-980. 2020
Correction to: Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. 31:981-981. 2020
Hypophosphatasia: Canadian update on diagnosis and management. 30:1713-1722. 2019
Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study. 30:1635-1644. 2019
Correction to: Hypophosphatasia: Canadian update on diagnosis and management. 30:1541-1541. 2019
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. 30:817-828. 2019
Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. 30:45-57. 2019
Build better bones with exercise (B3E pilot trial): results of a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in older women with vertebral fracture. 29:2545-2556. 2018
“Left to my own devices, I don’t know”: using theory and patient-reported barriers to move from physical activity recommendations to practice. 29:1081-1091. 2018
Exercise to improve functional outcomes in persons with osteoporosis: a systematic review and meta-analysis. 29:265-286. 2018
The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study. 29:329-337. 2018
Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis. 29:5-17. 2018
Self-perception of fracture risk: what can it tell us?. 28:3495-3500. 2017
Musculoskeletal health in newly diagnosed children with Crohn’s disease. 28:3169-3177. 2017
Association of gastrointestinal events with quality of life and treatment satisfaction in osteoporosis patients: results from the Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study (MUSIC OS). 28:2867-2876. 2017
Osteoporosis exercise knowledge and education in medicine and nursing: response to comments by Nguyen. 28:3071-3073. 2017
Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. 28:1817-1833. 2017
“I do not have time. Is there a handout I can use?”: combining physicians’ needs and behavior change theory to put physical activity evidence into practice. 28:1953-1963. 2017
Facilitators and barriers to exercise adherence in patients with osteopenia and osteoporosis: a systematic review. 28:735-745. 2017
Biologic therapies and bone loss in rheumatoid arthritis. 28:429-446. 2017
The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. 28:597-608. 2017
Impact of vitamin D replacement in adults and elderly in the Middle East and North Africa: a systematic review and meta-analysis of randomized controlled trials. 28:35-46. 2017
Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. 28:1-19. 2017
Retraction to: Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. 28:421-421. 2017
The current economic burden of illness of osteoporosis in Canada. 27:3023-3032. 2016
Intensity is a subjective construct. 27:2391-2392. 2016
The management of osteoporosis in children. 27:2147-2179. 2016
Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis. 27:1989-1998. 2016
Total medical costs of treating femoral neck fracture patients with hemi- or total hip arthroplasty: a cost analysis of a multicenter prospective study. 27:1999-2008. 2016
Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. 27:1709-1718. 2016
Bisphosphonate drug holidays: we reap what we sow. 27:849-852. 2016
Comparative trends in incident fracture rates for all long-term care and community-dwelling seniors in Ontario, Canada, 2002–2012. 27:887-897. 2016
Differential sclerostin and parathyroid hormone response to exercise in boys and men. 27:1245-1249. 2016
Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. 27:1227-1238. 2016
Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. 27:853-859. 2016
Trabecular bone score in kidney transplant recipients. 27:1115-1121. 2016
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. 26:2763-2771. 2015
Too Fit To Fracture: outcomes of a Delphi consensus process on physical activity and exercise recommendations for adults with osteoporosis with or without vertebral fractures. 26:891-910. 2015
International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. 26:419-420. 2015
Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. 26:361-372. 2015
A Frailty Index predicts 10-year fracture risk in adults age 25 years and older: results from the Canadian Multicentre Osteoporosis Study (CaMos). 25:2825-2832. 2014
Predictors of low bone mineral density of the stroke-affected hip among ambulatory individuals with chronic stroke. 25:2631-2638. 2014
Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). 25:1473-1481. 2014
Too Fit To Fracture: a consensus on future research priorities in osteoporosis and exercise. 25:1465-1472. 2014
The societal costs of femoral neck fracture patients treated with internal fixation. 25:875-885. 2014
Too Fit To Fracture: exercise recommendations for individuals with osteoporosis or osteoporotic vertebral fracture. 25:821-835. 2014
Inclinometer-based measures of standing posture in older adults with low bone mass are reliable and associated with self-reported, but not performance-based, physical function. 25:721-728. 2014
Scores on the Safe Functional Motion test predict incident vertebral compression fracture. 25:543-550. 2014
Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. 25:627-637. 2014
Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. 25:85-95. 2014
Exploring the determinants of fracture risk among individuals with spinal cord injury. 25:177-185. 2014
Cancer-associated bone disease. 24:2929-2953. 2013
Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. 24:2763-2764. 2013
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. 24:1161-1168. 2013
Estimating the excess costs for patients with incident fractures, prevalent fractures, and nonfracture osteoporosis. 24:581-593. 2013
Non-hip, non-spine fractures drive healthcare utilization following a fracture: the Global Longitudinal Study of Osteoporosis in Women (GLOW). 24:59-67. 2013
Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women. 23:2863-2871. 2012
Treatment failure in osteoporosis. 23:2769-2774. 2012
The burden of illness of osteoporosis in Canada. 23:2591-2600. 2012
A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. 23:2257-2276. 2012
Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women. 23:2179-2188. 2012
Comment on: cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. 23:2063-2065. 2012
Frailty and sarcopenia: definitions and outcome parameters. 23:1839-1848. 2012
Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. 23:1475-1480. 2012
Ankle fractures do not predict osteoporotic fractures in women with or without diabetes. 23:957-962. 2012
Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. 23:1075-1082. 2012
Estimation of the lifetime risk of hip fracture for women and men in Canada. 23:921-927. 2012
Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome. 23:751-760. 2012
A reappraisal of generic bisphosphonates in osteoporosis. 23:213-221. 2012
Impact of a centralized osteoporosis coordinator on post-fracture osteoporosis management: a cluster randomized trial. 23:87-95. 2012
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. 23:351-363. 2012
The effect of exercise on pQCT parameters of bone structure and strength in postmenopausal women—a systematic review and meta-analysis of randomized controlled trials. 23:39-51. 2012
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial. 22:2539-2549. 2011
Association between timing of zoledronic acid infusion and hip fracture healing. 22:2329-2336. 2011
Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts. 22:1873-1883. 2011
Fruit and vegetable intake and bone health in women aged 45 years and over: a systematic review. 22:1681-1693. 2011
Deleting Rac1 improves vertebral bone quality and resistance to fracture in a murine ovariectomy model. 22:1481-1492. 2011
Osteoporosis quality indicators using healthcare utilization data. 22:1335-1342. 2011
Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. 22:817-827. 2011
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. 22:967-982. 2011
Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. 22:829-837. 2011
Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study. 22:789-796. 2011
Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW). 22:27-35. 2011
Effect of whole-body vibration on BMD: a systematic review and meta-analysis. 21:1969-1980. 2010
The Ontario Osteoporosis Strategy: implementation of a population-based osteoporosis action plan in Canada. 21:903-908. 2010
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?. 20:1785-1793. 2009
Osteoporosis management among residents living in long-term care. 20:1471-1478. 2009
Monitoring strontium ranelate therapy in patients with osteoporosis. 20:1101-1106. 2009
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. 20:1107-1116. 2009
Glucocorticoid-induced osteoporosis. 20:239-240. 2009
RETRACTED ARTICLE: Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study. 20:737-744. 2009
The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. 20:703-714. 2009
Risk factors for low BMD in healthy men age 50 years or older: a systematic review. 20:507-518. 2009
A demonstration project of a multi-component educational intervention to improve integrated post-fracture osteoporosis care in five rural communities in Ontario, Canada. 20:265-274. 2009
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. 20:291-297. 2009
Accounting for body size deviations when reporting bone mineral density variables in children. 20:113-121. 2009
Risk factors for low bone mass in healthy 40–60 year old women: A systematic review of the literature. 20:1-21. 2009
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. 19:687-697. 2008
The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. 19:581-587. 2008
Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis. 18:1091-1100. 2007
Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada. 18:819-827. 2007
Non-compliance: the Achilles' heel of anti-fracture efficacy. 18:711-719. 2007
Reduced loading due to spinal-cord injury at birth results in “slender” bones: a case study. 18:117-120. 2007
A simple method for determining the probability a new vertebral fracture is present in postmenopausal women with osteoporosis. 17:379-386. 2006
Determinants of health-related quality of life in women with vertebral fractures. 17:355-363. 2006
Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study. 17:217-224. 2006
Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. 16:1461-1474. 2005
Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). 16:1836-1840. 2005
Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos). 16:568-578. 2005
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. 16:403-410. 2005
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. 16:208-215. 2005
Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. 14:913-917. 2003
The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos). 14:895-904. 2003
Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. 14:808-813. 2003
Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. 14:677-682. 2003
Effects of Raloxifene on Fracture Severity in Postmenopausal Women with Osteoporosis: Results from the MORE Study. 13:907-913. 2002
The Decision to Accept Treatment for Osteoporosis Following Hip Fracture: Exploring the Woman’s Perspective Using a Stage-of-Change Model. 13:560-564. 2002
Direct Medical Costs Attributable to Osteoporotic Fractures. 13:323-330. 2002
The Influence of Osteoporotic Fractures on Health-Related Quality of Life in Community-Dwelling Men and Women across Canada. 12:903-908. 2001
Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions. 12:849-857. 2001
Lengthy Hospitalization Associated with Vertebral Fractures Despite Control for Comorbid Conditions. 12:870-874. 2001
Economic Implications of Hip Fracture: Health Service Use, Institutional Care and Cost in Canada. 12:271-278. 2001
A Meta-analysis of Etidronate for the Treatment of Postmenopausal Osteoporosis. 12:140-151. 2001
Fluoride for the Treatment of Postmenopausal Osteoporotic Fractures: A Meta-Analysis. 11:727-738. 2000
Predicting Subsequent Bone Density Response to Intermittent Cyclical Therapy with Etidronate from Initial Density Response in Patients with Osteoporosis. 11:607-614. 2000
Development and Validation of the Mini-Osteoporosis Quality of Life Questionnaire (OQLQ) in Osteoporotic Women with Back Pain due to Vertebral Fractures. Osteoporosis Quality of Life Study Group. 10:207-213. 1999
Measuring Quality of Life in Women with Osteoporosis. 7:478-487. 1997
Do hip protectors decrease the risk of hip fracture in institutional- and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials

Osteoporosis International Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)